SOUTH SAN FRANCISCO, Calif., April 11, 2019 (GLOBE NEWSWIRE) — Surrozen Inc., a company discovering and developing novel antibodies for regenerative medicine with a focus on specific control of the Wnt signaling pathway, today announced the appointment of Trudy Vanhove, MD, PhD, MBA, as Chief Medical Officer. An experienced biopharmaceutical executive, Dr. Vanhove brings to Surrozen more than 20 years of clinical drug development and medical affairs experience across small and large biopharmaceutical companies.
“We are excited to welcome Trudy to the Surrozen team as we expand our capabilities to enable development of our bi-specific antibodies. She brings extensive experience across all phases of clinical development including a deep understanding of biologics drug development,” said Craig Parker, CEO of Surrozen. “As we transition Surrozen into later-stage preclinical development, Trudy will play a critical role in guiding and implementing our preclinical and clinical plans across a pipeline of selective Wnt pathway targeted antibodies.”
“Surrozen is establishing itself at the forefront of regenerative medicine through selective modulation of the Wnt pathway,” said Dr. Vanhove. “Its two bi-specific antibody technologies can selectively stimulate disease-specific tissue regeneration and offer a unique approach to treating diseases characterized by severe tissue damage. I look forward to joining the Surrozen team as we work towards advancing development candidates.”
Dr. Vanhove previously served as Vice President of medical affairs and, subsequently, R&D search and evaluation at Jazz Pharmaceuticals since 2012. Prior to Jazz Pharmaceuticals, she was Vice President, medical affairs at Depomed, Vice President clinical development at NeurogesX and a Medical Director and project team leader at XOMA. She began her career as a Medical Director at Abbott Laboratories in 1996. Dr. Vanhove earned an MD and a PhD in pharmacology from the Catholic University in Leuven, Belgium. She completed a fellowship in clinical pharmacology at Stanford University and received an MBA from St. Mary’s College in California. Dr. Vanhove has authored, or co-authored, dozens of peer-reviewed articles, and is an inventor on numerous patents.
Surrozen Inc. is a biopharmaceutical company focused on harnessing the Wnt pathway for applications in regenerative medicine. Founded on breakthrough science from Stanford University and backed by The Column Group, Surrozen is implementing Wnt and R-spondin mimetic approaches with the potential to unlock stem cell control of regeneration in a wide array of human tissues. The Company is building a broad pipeline of selective Wnt pathway targeted antibodies that drive tissue regeneration, with the goal of addressing a variety of critical unmet medical needs. For more information, please visit surrozen.com.